|
|
|
| Clinical Efficacy of Two Administrations of Bromocriptine in the Treatment of Female Hyperprolactinemia Infertility |
| XU Xiao-hong, ZHANG Lei, LI Ning, et al |
| People's Hospital of Ganzi Garze Tibetan Prefecture,Sichuan province, Ganzi 626000 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy of two administrations of bromocriptine in the treatment of female hyperprolactinemia (HPRL) infertility.【Methods】A total of 87 cases of HPRL patients admitted from May 2014 to May 2016 in our hospital were retrospectively divided into control group and observation group according to the way of administration of bromocriptine. The control group was treated with oral bromocriptine treatment while the observation group were treated by vaginal administration of bromocriptine . Clinical symptoms, serum follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), prolactin (PRL) levels, ovulation rate, pregnancy rate, abortion rate and adverse reaction rate after treatment in the two groups were compared. 【Results】The number of patients with rare menstruation, amenorrhea, galactorrhea, hirsutism and headache in two groups after treatment was lower than that before treatment ( P < 0.05). After treatment, the levels of FSH and E2 in two groups were higher than those before treatment, while the levels of LH and PRL were lower than those before treatment ( P < 0.05).However, no significant differences were shown between the two groups ( P > 0.05). There were no significant differences in ovulation rate, pregnancy rate and abortion rate between the two groups ( P > 0.05). The adverse reaction rate in the observation group was lower than that in the control group ( P < 0.05). 【Conclusion】Oral and vaginal administration of bromocriptine are effective in treating female hyperprolactinemia infertility. It can improve the serum sex hormone levels and control the level of serum PRL. However, the incidence of adverse reactions to vaginal administration is low, which is worthy of clinical application.
|
|
Received: 29 November 2017
|
|
|
|
|
|
[1] Brown RS,Kokay IC,Phillipps HR, et al . Conditional deletion of the prolactin receptor reveals functional subpopulations of dopamine neurons in the arcuate nucleus of the hypothalamus[J]. J Neurosci, 2016,36(35):9173-9185.
[2] 王娟,阮祥燕,殷冬梅,等. 溴隐亭不同给药方案治疗高泌乳素血症女性性腺激素促排卵临床研究[J].现代生物医学进展,2017,17(1):130-132.
[3] 李娟,郑巧玲,周琼,等. 溴隐亭治疗妊娠垂体泌乳素瘤患者的安全性研究进展[J].实用药物与临床,2015,18(12):1505-1508.
[4] 石苗. 溴隐亭对高泌乳素血症女性促性腺激素诱导排卵的影响[J].中国妇幼保健, 2015,30(30):5157-5159.
[5] 陈宏谋,郑捷敏,闫宪磊,等. 溴隐亭对垂体泌乳素腺瘤血管形成的影响及其分子作用机制研究[J].实用心脑肺血管病杂志,2016,24(3):43-48.
[6] 黄青,吴乙璇,刘海英,等. 溴隐亭预防卵巢过度刺激综合征的疗效观察[J].中国妇幼保健,2015,30(19):3214-3217.
[7] 黄燕冰,黄利娟,邓跃飞,等. 甲磺酸溴隐亭治疗垂体催乳素大腺瘤合并不孕症的临床观察[J].中国妇产科临床杂志,2015,1(4):305-308.
[8] 裴雪婷,纪冬梅,周平. 肛内应用溴隐亭预防中重度卵巢过度刺激综合征的临床研究[J].实用妇产科杂志,2015,31(11):855-857.
[9] 连伟,刘念,王任直,等. 垂体催乳素腺瘤患者妊娠期服用溴隐亭的疗效分析[J].中华医学杂志,2015,95(7):511-514.
[10] 靳团娥. 抑乳颗粒联合甲磺酸溴隐亭片治疗特发性高泌乳素血症不孕症临床观察[J].西部中医药,2017,30(3):104-106. |
|
|
|
2018, Vol. 35 
